{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T23:10:23Z","timestamp":1736637023291,"version":"3.32.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2006,12,1]],"date-time":"2006-12-01T00:00:00Z","timestamp":1164931200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2006,12]]},"DOI":"10.1007\/s00108-006-1754-0","type":"journal-article","created":{"date-parts":[[2006,11,10]],"date-time":"2006-11-10T14:37:03Z","timestamp":1163169423000},"page":"1263-1268","source":"Crossref","is-referenced-by-count":2,"title":["Therapie der sekund\u00e4ren Arthropathien","Therapy for secondary arthropathies"],"prefix":"10.1007","volume":"47","author":[{"given":"A.","family":"G\u00f6dde","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"M\u00fcller-Ladner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"1754_CR1","first-page":"241","volume":"22","author":"Abu-Shakra","year":"1995","unstructured":"Abu-Shakra M, Gladman DD, Thorne JC et al. (1995) Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome. J Rheumatol 22: 241\u2013245","journal-title":"J Rheumatol"},{"key":"1754_CR2","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/art.20967","volume":"52","author":"Antoni","year":"2005","unstructured":"Antoni CE, Kavanaugh A, Kirkham B et al. (2005) Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 52: 1227\u20131236","journal-title":"Arthritis Rheum"},{"key":"1754_CR3","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.1964.03070100037007","volume":"189","author":"Blacki","year":"1964","unstructured":"Blacki RL, O\u2019Brien WM, Vanscott EJ et al. (1964) Methotrexate therapy in psoriatic arthritis: double-blind study on 21 patients. JAMA 189: 743\u2013747","journal-title":"JAMA"},{"key":"1754_CR4","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1001\/jama.295.19.2275","volume":"295","author":"Bongartz","year":"2006","unstructured":"Bongartz T, Sutton AJ, Sweeting MJ et al. (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295: 2482","journal-title":"JAMA"},{"key":"1754_CR5","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","volume":"54","author":"Breedveld","year":"2006","unstructured":"Breedveld FC, Weisman MH, Kavanaugh AF et al. (2006) The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54: 26\u201337","journal-title":"Arthritis Rheum"},{"key":"1754_CR6","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1002\/art.1780391210","volume":"39","author":"Clegg","year":"1996","unstructured":"Clegg DO, Reda DJ, Mejias E et al. (1996) Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 39: 2013\u20132020","journal-title":"Arthritis Rheum"},{"key":"1754_CR7","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1002\/art.1780391211","volume":"39","author":"Clegg","year":"1996","unstructured":"Clegg DO, Reda DJ, Weisman MH et al. (1996) Comparison of sulfasalazine and placebo in the treatment of reactive arthritis (Reiter\u2019s syndrome). A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 39: 2021\u20132027","journal-title":"Arthritis Rheum"},{"key":"1754_CR8","first-page":"872","volume":"19","author":"Espinoza","year":"1992","unstructured":"Espinoza LR, Zakraoui L, Espinoza CG et al. (1992) Psoriatic arthritis: clinical response and side effects to methotrexate therapy. J Rheumatol 19: 872\u2013877","journal-title":"J Rheumatol"},{"key":"1754_CR9","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/art.21323","volume":"53","author":"Flagg","year":"2005","unstructured":"Flagg SD, Meador R, Hsia E et al. (2005) Decreased pain and synovial inflammation after etanercept therapy in patients with reactive and undifferentiated arthritis: an open-label trial. Arthritis Rheum 53: 613\u2013617","journal-title":"Arthritis Rheum"},{"key":"1754_CR10","doi-asserted-by":"crossref","first-page":"ii14","DOI":"10.1136\/ard.2004.032482","volume":"64","author":"Gladman","year":"2005","unstructured":"Gladman DD, Antoni C, Mease P et al. (2005) Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 64 (Suppl 2): ii14\u2013ii17","journal-title":"Ann Rheum Dis"},{"key":"1754_CR11","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1002\/art.20253","volume":"50","author":"Kaltwasser","year":"2004","unstructured":"Kaltwasser JP, Nash P, Gladman D et al. (2004) Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 50: 1939\u20131950","journal-title":"Arthritis Rheum"},{"key":"1754_CR12","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1136\/ard.2003.010710","volume":"63","author":"Kvien","year":"2004","unstructured":"Kvien TK, Gaston JS, Bardin T et al. (2004) Three month treatment of reactive arthritis with azithromycin: a EULAR double blind, placebo controlled study. Ann Rheum Dis 63: 1113\u20131119","journal-title":"Ann Rheum Dis"},{"key":"1754_CR13","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1136\/ard.62.7.655","volume":"62","author":"Laasila","year":"2003","unstructured":"Laasila K, Laasonen L, Leirisalo-Repo M (2003) Antibiotic treatment and long term prognosis of reactive arthritis. Ann Rheum Dis 62: 655\u2013658","journal-title":"Ann Rheum Dis"},{"key":"1754_CR14","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/03009740500202540","volume":"34","author":"Leirisalo-Repo","year":"2005","unstructured":"Leirisalo-Repo M (2005) Reactive arthritis. Scand J Rheumatol 34: 251\u2013259","journal-title":"Scand J Rheumatol"},{"key":"1754_CR15","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1136\/ard.2004.020719","volume":"63","author":"Mease","year":"2004","unstructured":"Mease P (2004) TNF alpha therapy in psoriatic arthritis and psoriasis. Ann Rheum Dis 63: 755\u2013758","journal-title":"Ann Rheum Dis"},{"key":"1754_CR16","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s00393-004-0563-x","volume":"63","author":"Rihl","year":"2004","unstructured":"Rihl M, Kellner H (2004) Die Arthropathie der heredit\u00e4ren H\u00e4mochromatose. Z Rheumatol 63: 22\u201329","journal-title":"Z Rheumatol"},{"key":"1754_CR17","first-page":"2274","volume":"28","author":"Salvarani","year":"2001","unstructured":"Salvarani C, Macchioni P, Olivieri I et al. (2001) A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol 28: 2274\u20132282","journal-title":"J Rheumatol"},{"key":"1754_CR18","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1007\/s100510170345","volume":"19","author":"Sarzi-Puttini","year":"2001","unstructured":"Sarzi-Puttini P, Santandrea S, Boccassini L et al. (2001) The role of NSAIDs in psoriatic arthritis: evidence from a controlled study with nimesulide. Clin Exp Rheumatol 19: S17\u2013S20","journal-title":"Clin Exp Rheumatol"},{"key":"1754_CR19","first-page":"589","volume":"13","author":"Spadaro","year":"1995","unstructured":"Spadaro A, Riccieri V, Sili-Scavalli A et al. (1995) Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study. Clin Exp Rheumatol 13: 589\u2013593","journal-title":"Clin Exp Rheumatol"},{"key":"1754_CR20","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1053\/jhep.2001.24783","volume":"33","author":"Tavill","year":"2001","unstructured":"Tavill AS (2001) Diagnosis and management of hemochromatosis. Hepatology 33: 1321\u20131328","journal-title":"Hepatology"},{"key":"1754_CR21","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.1780270403","volume":"27","author":"Willkens","year":"1984","unstructured":"Willkens RF, Williams HJ, Ward JR et al. (1984) Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum 27: 376\u2013381","journal-title":"Arthritis Rheum"},{"key":"1754_CR22","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1136\/ard.59.7.565","volume":"59","author":"Yli-Kerttula","year":"2000","unstructured":"Yli-Kerttula T, Luukkainen R, Yli-Kerttula U et al. (2000) Effect of a three month course of ciprofloxacin on the outcome of reactive arthritis. Ann Rheum Dis 59: 565\u2013570","journal-title":"Ann Rheum Dis"},{"key":"1754_CR23","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1136\/ard.62.9.880","volume":"62","author":"Yli-Kerttula","year":"2003","unstructured":"Yli-Kerttula T, Luukkainen R, Yli-Kerttula U et al. (2003) Effect of a three month course of ciprofloxacin on the late prognosis of reactive arthritis. Ann Rheum Dis 62: 880\u2013884","journal-title":"Ann Rheum Dis"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-006-1754-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-006-1754-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-006-1754-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T22:47:53Z","timestamp":1736635673000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-006-1754-0"}},"subtitle":["Von der Psoriasis \u00fcber den Morbus Reiter bis zur H\u00e4mochromatose","From psoriasis and Reiter\u2019s disease to hemochromatosis"],"short-title":[],"issued":{"date-parts":[[2006,12]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["1754"],"URL":"https:\/\/doi.org\/10.1007\/s00108-006-1754-0","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"type":"print","value":"0020-9554"},{"type":"electronic","value":"1432-1289"}],"subject":[],"published":{"date-parts":[[2006,12]]}}}